Ng, Weng

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology

Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers

Cited by 690

Web-Based Patient-Reported Outcome Measures for Personalized Treatment and Care (PROMPT-Care): Multicenter Pragmatic Nonrandomized Trial

Girgis, A., Durcinoska, I., Arnold, A., Descallar, J., Kaadan, N., Koh, E.-S., Miller, A., Ng, W., Carolan, M., Della-Fiorentina, S. A., et al. (2020) · Journal of Medical Internet Research

Cancer survivorship and careMobile Health and mHealth Applications

Cited by 92